CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Broncho-Vaxom®Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.

NCT04496245 Respiratory Viral Infection Covid19 Drug: Broncho-Vaxom®
MeSH:Virus Diseases

Primary Outcomes

Description: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3 months.

Measure: Acute Respiratory Infection necessitating workforce removal

Time: 3 months

Secondary Outcomes

Description: The time to the first ARI necessitating workforce removal in the initial treatment and wait-list control groups.

Measure: Time to ARI necessitating workforce removal.

Time: 12 months

Description: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 6 and 12 monhts

Measure: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal

Time: 12 months

Description: The proportion of HCW in the initial treatment and wait-list control group with Cov infection documented by molecular techniques of seroconversion

Measure: The proportion of HCW with documented Cov infection.

Time: 12 months

Description: The time to the first LRI necessitating workforce removal in the initial treatment and wait-list control groups.

Measure: Time to Lower respiratory infection (LRI) necessitating workforce removal.

Time: 12 months

Description: The proportion of Health Care Workers contracting LRI necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3, 6 and 12 monhts

Measure: The proportion of Health Care Workers contracting a LRI necessitating workforce removal

Time: 12 months

Description: The proportion of HCW in the initial treatment and wait-list control group with LRI due to Cov infection documented by molecular techniques of seroconversion

Measure: The proportion of HCW with documented Cov LRI.

Time: 12 months

No related HPO nodes (Using clinical trials)